AACHEN, Germany, Nov. 2, 2022 /PRNewswire/ Grünenthal today announced the successful completion of its acquisition of NebidoTM from Bayer for €495 million. "Testosterone deficiency affects
Grünenthal acquires NebidoTM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal's EBITDA in 2023.NebidoTM is the gold standard for the treatment
LEVERKUSEN (dpa-AFX) - Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L), a German pharma and life sciences firm, said on Thursday that it has inked a deal with Grünenthal, a company focused on pain management
CIUDAD DE MÉXICO, septiembre 28 (EL UNIVERSAL).- Senadores del PAN presentarán una queja ante el Consejo de la Judicatura Federal (CJF) para que inves.
Santiago de Chile, 15 sep (EFE).- Las autoridades chilenas decidieron este miércoles que el icónico Festival Internacional de la Canción de Viña del M.